Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA, United States.
Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA, United States; Jefferson Vaccine Center, Thomas Jefferson University, Philadelphia, PA, United States.
Curr Opin Virol. 2021 Aug;49:52-57. doi: 10.1016/j.coviro.2021.04.008. Epub 2021 May 4.
SARS-CoV-2 has been detected in more than 141 million people and caused more than 3 million deaths worldwide. To reduce the additional loss of millions of lives until natural immunity is reached, researchers have focused on the only known method to stop the COVID-19 pandemic: vaccines. The pandemic has propelled high-speed vaccine development, some based on novel technology previously not utilized in the vaccine field. The new technology opens new possibilities and comes with challenges because the long-term performance of the new platforms is unknown. Here we review the current leading vaccine candidates against COVID-19 and outline the advantages and disadvantages as well as the unknowns of each candidate.
SARS-CoV-2 已在全球超过 1.41 亿人身上检测到，并导致超过 300 万人死亡。为了减少在自然免疫力达到之前数以百万计的生命损失，研究人员专注于阻止 COVID-19 大流行的唯一已知方法：疫苗。这场大流行推动了疫苗的高速研发，其中一些基于以前未在疫苗领域使用的新技术。新技术带来了新的可能性和挑战，因为新平台的长期性能尚不清楚。在这里，我们回顾了目前针对 COVID-19 的领先疫苗候选者，并概述了每种候选者的优缺点和未知因素。
